Strong Performance in Proprietary Drug Delivery Systems
Core sales for proprietary drug delivery systems grew 4%, with 12 consecutive quarters of growth, including six with double-digit growth. Success driven by record launches, new innovations, and product reliability.
Recognition for Sustainability Efforts
Aptar was named one of Barron's most sustainable US companies for the seventh consecutive year and achieved EcoVadis' Platinum level rating, placing them among the top 1% of over 150,000 companies rated.
Positive Developments in Beauty and Closures Segments
Sequential improvement in Beauty sales, notably in Europe and China. Closures segment showed product sales growth in all end markets, with improvements in utilization rates and cost management.
Innovations and New Product Launches
New technologies and product launches in Pharma, Beauty, and Closures segments, including a nasal delivery system in Germany and an ophthalmic dispenser in China.
Share Repurchase Program
Aptar ramped up share repurchases, buying over 0.5 million shares for approximately $80 million, emphasizing belief in the company's future trajectory.